DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population

Information source: The George Institute for Global Health, China
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Telmisartan (Drug); Hydrochlorothiazide (Drug)

Phase: N/A

Status: Completed

Sponsored by: The George Institute for Global Health, China

Official(s) and/or principal investigator(s):
Zhang Pu Hong, Principal Investigator, Affiliation: The George Institute

Summary

In this research, the investigators aim to compare the antihypertensive efficacy and safety of monotherapy of routine dose angiotensin receptor antagonist telmisartan (ARB) and diuretic Hydrochlorothiazide (HCTZ) in high sodium intake patients with mild to moderate hypertension. The research will be conducted in the rural area in Hebei province, where people have a high sodium diet in their daily life. The 1200 eligible subjects will be drawn from 12 local county-level hospitals. Subjects will be randomly allocated in double-blind manner into ARB or HCTZ group to be administered telmisartan 40mg per day or hydrochlorothiazide 25mg per day respectively. After two-month treatment, the investigators will evaluate and compare the antihypertensive efficacy and safety between the two therapies. The first objective of the research is to compare the antihypertensive efficacy of monotherapy of routine dose of angiotensin receptor antagonist telmisartan (ARB) and diuretic Hydrochlorothiazide (HCTZ) in high sodium intake patients with mild to moderate hypertension. The second objective is to compare the safety between the two therapies applied. Null Hypothesis-H0: There will be no efficacy differences of lowering the systolic pressure between treating high sodium intake patients with mild to moderate hypertension with telmisartan and hydrochlorothiazide. Alternative Hypothesis-H1: There will be efficacy differences of lowering the systolic pressure between treating high sodium intake patients with mild to moderate hypertension with telmisartan and hydrochlorothiazide. This research is a multicenter randomized double-blinded parallel controlled trial targeting on high sodium intake patients with mild to moderate hypertension in China. The eligible 1200 subjects will be randomly divided into ARB and HCTZ two groups, treated with monotherapy of telmisartan 40mg per day or hydrochlorothiazide 25mg per day respectively. Then, the compliance of the patients will be followed after a week. The investigators will evaluate the efficacy of blood pressure control and the safety of the medicines after one month and two months of the beginning of therapies. Figure 1 shows the research process.

Clinical Details

Official title: Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The difference between 2 groups of the decrease ranges of SBPs before and after the intervention of the subjects

Secondary outcome: The between-group difference of the decrease ranges of DBPs before and after the intervention of the subjects

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age≥18

- Essential hypertension: systolic blood pressure (SBP) is between 140mmHg-179mmHg and

diastolic blood pressure (DBP)<110mmHg OR DBP is between 90mmHg-109mmHg and SBP<180mmHg.

- Hypertension patients diagnosed by spot urine test (urine sodium≥200mmol/24h).

- Subjects are not using antihypertensive medicines or medicines which affect the blood

pressure within a week.

- Subjects volunteer to be brought in the research and have signed informed consent

form, given that they have understood the research content. Exclusion Criteria:

- Females who are already pregnant, in lactation and intend to be pregnant.

- Patients who have seriously allergic reaction or angioneurotic edema when taking ARB;

Patients who have allergic history of thiazide diuretic (HCTZ) or sulfonamides.

- Patients who do not want to stop or have to take the medicines which are also

antihypertensive or affect the blood pressure, other than which provided by the research.

- Stroke or CHD patients who are diagnosed within 6 months. CHD patients are identified

by being diagnosed by coronary arteriography or coronary CT angiography, having received coronary stent or coronary artery bypass surgery, or being diagnosed with acute myocardial infarction. Stroke patients are identified by being diagnosed with cerebral thrombosis, cerebral embolism, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack.

- Patients who are clearly diagnosed with following diseases: Congenital disease,

myocardiopathy, serious arrhythmia, pulmonary heart disease, various of cardiac failure.

- Patients who are clearly diagnosed with following symptoms or diseases: Proteinuria

or heavy proteinuria, renal insufficiency or serious renal function damage, hepatic insufficiency or serious hepatic function damage; retinal exudates or hemorrhage, or papilledema.

- Patients who are clearly diagnosed with serious or deadly diseases in other systems.

- Patients who get dementia or other serious diseases cannot cooperate with

researchers.

- Patients who drink 200g white spirits per day in past week.

- Patients who meet other situations which are considered to be inappropriate to be

enrolled into the study by researchers.

Locations and Contacts

Boye hospital, Baoding, Hebei 071300, China

Central hospital in Baigou, Baoding, Hebei 074004, China

Chinese Traditional Medicine Hospital of Anguo, Baoding, Hebei 071200, China

Gaobeidian hospital, Baoding, Hebei 074000, China

Gaoyang hospital, Baoding, Hebei 071500, China

Lixian chinese traditional medicine hospital, Baoding, Hebei 071400, China

Mancheng Hospital, Baoding, Hebei 072150, China

People's hospital in Rongcheng, Baoding, Hebei 071700, China

People's hospital of Tangxian, Baoding, Hebei 072350, China

Shunping Hospital, Baoding, Hebei 072250, China

The second hospital of Lai Shui, Baoding, Hebei 074100, China

Wangdu hospital, Baoding, Hebei 072450, China

Wenan Hospital, Lanfang, Hebei 065800, China

Dacheng chinese traditional medicine hospital, Langfang, Hebei 065900, China

Additional Information

Starting date: October 2014
Last updated: March 9, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017